Lv22
188 积分 2025-10-20 加入
Ponatinib superior to imatinib in Ph(+) ALL
18天前
已完结
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study
18天前
已完结
Real-world Efficacy and Safety of Flumatinib as the First-line Treatment in Patients With de novo Philadelphia-positive Acute Lymphoblastic Leukemia
18天前
已完结
Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data
18天前
已完结
Phase III Data Support Chemo-Free Approach to ALL
18天前
已完结
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia
18天前
已完结
Comparison of third-generation tyrosine kinase inhibitor (TKI) ponatinib with first- and second-generation TKIs for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and bias-corrected meta-analysis
18天前
已完结
Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
18天前
已完结
Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions
18天前
已完结
How I treat acute lymphoblastic leukemia in the era of immunotherapy while revisiting the myth of second remission
18天前
已完结
皖公网安备34019202002308
